In November 2021, Abevmy and Aybintio were approved for medical use in Canada. In April 2022, bevacizumab-maly (Alymsys) was approved for medical use in the United States. In September 2022, bevacizumab-adcd (Vegzelma) was approved for medical use in the United States. Research A study released in April 2009, found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. Bevacizumab has been tested in ovarian cancer where it has shown improvement in progression-free survival but not in overall survival. and glioblastoma multiforme where it failed to improve overall survival. Bevacizumab has been investigated as a possible treatment of pancreatic cancer, as an addition to chemotherapy, but studies have shown no improvement in survival. It may also cause higher rates of high blood pressure, bleeding in the stomach and intestine, and intestinal perforations. The drug has also undergone trials as an addition to established chemotherapy protocols and surgery in the treatment of pediatric osteosarcoma, and other sarcomas, such as leiomyosarcoma. Bevacizumab has been studied as a treatment for cancers that grow from the nerve connecting the ear and the brain. References Further reading External links Angiogenesis inhibitors Genentech brands Hoffmann-La Roche brands Monoclonal antibodies for tumors Ophthalmology drugs Orphan drugs Specialty drugs World Health Organization essential medicines Wikipedia medicine articles ready to translate